AbCellera (Nasdaq: ABCL) and Rallybio Corporation (Nasdaq: RLYB)
announced today that they have entered into a strategic alliance to
discover, develop, and commercialize novel antibody-based
therapeutics for rare diseases. This multi-year, multi-target
collaboration will combine AbCellera’s antibody discovery engine
with Rallybio’s clinical and commercial expertise in rare diseases
to identify optimal clinical candidates and ultimately deliver
therapies to patients.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20221129005959/en/
“It’s clear that we need to accelerate drug development for rare
diseases to address the enormous unmet medical need for these
patients,” said Carl Hansen, Ph.D., founder and CEO of AbCellera.
“Rallybio’s team has decades of experience in sourcing,
identifying, and evaluating therapeutic targets. By bringing
together Rallybio’s deep expertise in rare diseases with
AbCellera’s integrated technology for delivering clinical leads
with unmatched precision and speed, this partnership creates a
unique advantage that we believe will deliver new and
transformative medicines to patients.”
“AbCellera’s clinically validated discovery engine will
strengthen our efforts in identifying novel rare disease candidates
to add to our existing pipeline,” said Martin Mackay, Ph.D., Chief
Executive Officer of Rallybio. “We are excited to establish this
partnership and look forward to working closely with our colleagues
at AbCellera as we build novel medicines together.”
Under the terms of the agreement, AbCellera and Rallybio will
co-develop up to five rare disease therapeutic targets, which will
be chosen together by both companies. The collaboration will allow
Rallybio to add product candidates to its existing pipeline and
also provides the option for AbCellera to conduct process
development and clinical manufacturing activities. The
partnership’s first program will focus on addressing the
significant unmet therapeutic needs of patients with rare metabolic
diseases.
About AbCellera Biologics Inc. AbCellera is a technology
company that searches, decodes, and analyzes natural immune systems
to find antibodies that its partners can develop into drugs to
prevent and treat disease. AbCellera partners with drug developers
of all sizes, from large pharmaceutical to small biotechnology
companies, empowering them to move quickly, reduce cost, and tackle
the toughest problems in drug development. For more information,
please visit www.abcellera.com.
About Rallybio Rallybio is a clinical-stage biotechnology
company committed to identifying and accelerating the development
of life-transforming therapies for patients with severe and rare
diseases. Since its launch in January 2018, Rallybio has built a
portfolio of promising product candidates, which are now in
development to address rare diseases in the areas of hematology,
immuno-inflammation, maternal fetal health, and metabolic
disorders. The Company’s mission is being advanced by a team of
highly experienced biopharma industry leaders with extensive
research, development, and rare disease expertise. Rallybio is
headquartered in New Haven, Connecticut, with an additional
facility at the University of Connecticut’s Technology Incubation
Program in Farmington, Connecticut. For more information, please
visit www.rallybio.com.
AbCellera Forward-Looking Statements This press release
contains forward-looking statements, including statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The forward-looking statements are
based on management’s current beliefs and assumptions and on
information currently available to management. All statements
contained in this release other than statements of historical fact
are forward-looking statements, including statements regarding our
ability to develop, commercialize and achieve market acceptance of
our current and planned products and services, our research and
development efforts, and other matters regarding our business
strategies, use of capital, results of operations and financial
position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under "Risk Factors," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
Rallybio Forward-Looking Statements This press release
contains forward-looking statements that are based on our
management’s beliefs and assumptions and on information currently
available to management. In some cases, forward-looking statements
can be identified by terms such as “may,” “will,” “should,”
“expect,” “plan,” “anticipate,” “could,” “intend,” “target,”
“project,” “contemplate,” “believe,” “estimate,” “predict,”
“potential” or “continue” or the negative of these terms or other
similar expressions, although not all forward-looking statements
contain these words. Forward-looking statements in this press
release include, but are not limited to, statements concerning our
ability to identify acceptable targets, our ability to discover,
develop, and commercialize any product candidates that emerge from
the collaboration, either alone or together with AbCellera, and the
likelihood that we will successfully expand our pipeline through
the collaboration. The forward-looking statements in this press
release are only predictions and are based largely on management’s
current expectations and projections about future events and
financial trends that management believes may affect Rallybio’s
business, financial condition and results of operations. These
forward-looking statements speak only as of the date of this press
release and are subject to a number of known and unknown risks,
uncertainties and assumptions, including, but not limited to, our
ability to successfully initiate and conduct our planned clinical
trials, including the multiple ascending dose study for RLYB116,
and complete such clinical trials and obtain results on our
expected timelines, or at all, whether our cash resources will be
sufficient to fund our operating expenses and capital expenditure
requirements and whether we will be successful raising additional
capital, competition from other biotechnology and pharmaceutical
companies, and those risks and uncertainties described in
Rallybio’s filings with the U.S. Securities and Exchange Commission
(SEC), including Rallybio’s Quarterly Report on Form 10-Q for the
period ended September 30, 2022, and subsequent filings with the
SEC. The events and circumstances reflected in our forward-looking
statements may not be achieved or occur and actual future results,
levels of activity, performance and events and circumstances could
differ materially from those projected in the forward-looking
statements. Moreover, we operate in an evolving environment. New
risks and uncertainties may emerge from time to time, and it is not
possible for management to predict all risks and uncertainties.
Except as required by applicable law, we are not obligated to
publicly update or revise any forward-looking statements contained
in this press release, whether as a result of any new information,
future events, changed circumstances or otherwise.
Source: AbCellera Biologics Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221129005959/en/
AbCellera Contacts: Media: Jessica Yingling, Ph.D.;
media@abcellera.com, +1(236)521-6774 Business Development: Murray
McCutheon, Ph.D.; bd@abcellera.com, +1(604)559-9005 Investor
Relations: Josephine Hellschlienger, Ph.D.; ir@abcellera.com,
+1(778)729-9116 Rallybio Contacts: Investor Contacts Ami
Bavishi Head of Investor Relations and Corporate Communications
475-47-RALLY (Ext. 282) abavishi@rallybio.com Hannah Deresiewicz
Stern Investor Relations, Inc. 212-362-1200
hannah.deresiewicz@sternir.com Media Contact Tara DiMilia
908-369-7168 Tara.dimilia@tmstrat.com
AbCellera Biologics (NASDAQ:ABCL)
Historical Stock Chart
From Apr 2024 to May 2024
AbCellera Biologics (NASDAQ:ABCL)
Historical Stock Chart
From May 2023 to May 2024